THALIA THERAPEUTICS PLC (THAT) — Interim results for the six months ended 30 June 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the M4 Pharma PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. The company may not be in a position to answer every question received during the meeting itself. However, company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Nigel Theobold. Good afternoon to you. Good afternoon, and welcome, everybody. And thank you for coming along to listen today to our webinar on our latest interim results. We're just going to give you a a brief flavor of what we're doing this year. And for those some of the others who might be new, a bit of an overview of the company and our new technology, and then how it fits into our strategy into why we see this as a significant investable opportunity for everybody. So I'll I'll hand over to Alastair first, who's just gonna walk us through n four and the EVEC technology, and then I'll come back in and talk a little bit more about what we've been up to. Thanks, Nigel. Hello, everyone. I'm Alastair Smith, non executive director of n four pharma. Just gonna run through a couple of introductory slides and hand back to Nigel. I think it's probably useful to, you know, to paint a picture of where, you know, where the real value comes from in what we're doing in the Nuvec platform. And, know, the first thing to understand if you're not familiar with the with the company is that we're operating in the RNA therapeutic space, and that's a a very rapidly growing mar...